Synthesis and in vitro leishmanicidal activity of 2-(1-methyl-5-nitro-1H- imidazol-2-yl)-5-substituted-1,3,4-thiadiazole derivatives

European Journal of Medicinal Chemistry

Volumn 40, Issue 12, 2005, Pages 1346-1350

  Foroumadi, Alireza ^a,b   Emami, Saeed ^c   Pournourmohammadi, Shirin ^b   Kharazmi, Arsalan ^d   Shafiee, Abbas ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d Lica Pharmaceuticals A/S   (Denmark)

Author keywords

1,3,4 Thiadiazole; 5 Nitro 1H imidazole; Anti promastigote activity; Leishmania major

Indexed keywords

1 [5 (1 METHYL 5 NITROIMIDAZOL 2 YL) 1,3,4 THIADIAZOL 2 YL] 4 PHENYLPIPERAZINE; 1 [5 (1 METHYL 5 NITROIMIDAZOL 2 YL) 1,3,4 THIADIAZOL 2 YL]PIPERAZINE; 1 [5 (1 METHYL 5 NITROIMIDAZOL 2 YL) 1,3,4 THIADIAZOL 2 YL]PIPERIDINE; 4 [5 (1 METHYL 5 NITROIMIDAZOL 2 YL) 1,3,4 THIADIAZOL 2 YL]MORPHOLINE; 4 ACETYL 1 [5 (1 METHYL 5 NITROIMIDAZOL 2 YL) 1,3,4 THIADIAZOL 2 YL]PIPERAZINE; 4 BENZOYL 1 [5 (1 METHYL 5 NITROIMIDAZOL 2 YL) 1,3,4 THIADIAZOL 2 YL]PIPERAZINE; 4 METHYL 1 [5 (1 METHYL 5 NITROIMIDAZOL 2 YL) 1,3,4 THIADIAZOL 2 YL]PIPERAZINE; ANTILEISHMANIAL AGENT; STIBOGLUCONATE SODIUM; THIADIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG SYNTHESIS; IC 50; LEISHMANIA MAJOR; NONHUMAN; PROMASTIGOTE;

ANIMALS; ANTIPROTOZOAL AGENTS; LEISHMANIA MAJOR; MOLECULAR STRUCTURE; PARASITIC SENSITIVITY TESTS; STRUCTURE-ACTIVITY RELATIONSHIP; THIADIAZOLES;

EID: 27744523961     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2005.07.002     Document Type: Article

References (25)

1. F. Modabber Tropical disease research progress 1991-1992. UNDP/World Bank/WHO special program for Research and Training in Tropical Diseases 1993 World Health Organization Geneva, Switzerland 77 87
2. S.L. Croft Parasitology 114 1997 S3 S15
3. H.D. Engers, R. Bergquist, and F. Moddaber Dev. Biol. Stand. 87 1996 73 84
4. S.L. Croft Trends Pharmacol. Sci. 9 1988 376 381
5. J.D. Berman Rev. Infect. Dis. 10 1988 560 586
6. H.W. Murray Am. J. Trop. Med. Hyg. 71 2004 787 794
7. E. Handman Clin. Microbiol. Rev. 14 2001 229 243
8. M.D. Nair, and K. Nagarajan E. Jucker Progress in Drug Research: Nitroimidazoles as Chemotherapeutic Agents, vol. 27 1983 Birkauser Verlag Basel 163 252
9. J.P. Gangneux, M. Dullin, A. Sulahian, Y.J.F. Garin, and F. Derouin Antimicrob. Agents Chemother. 43 1999 172 174
10. B.K. Gosh, D.H. Ray, and A.N. Chatterjee J. Trop. Med. Hyg. 92 1989 383 386
11. A. Foroumadi, S. Pournourmohammadi, F. Soltani, M.A. Rezaee, S. Dabiri, A. Kharazmi, and A. Shafiee Bioorg. Med. Chem. Lett. 15 2005 1983 1985
12. D.I. Edwards J. Antimicrob. Chemother. 31 1993 9 20
13. G. Chauviere, B. Bouteille, B. Enanga, C. De Aluquerque, S.L. Croft, M. Dumas, and J. Perie J. Med. Chem. 46 2003 427 440
14. S.A. Carvalho, E.F. Da Silva, R.M. Santa-Rita, S.L. De Castro, and C.A.M. Fraga Bioorg. Med. Chem. Lett. 14 2004 5967 5970
15. G. Berkelhammer, and G. Asato Science 162 1968 1146 1147
16. A. Alemagna, T. Bacchetti, and P. Beltrama Tetrahedron 24 1968 3209 3217
17. A. Foroumadi, M. Daneshtalab, and A. Shafiee Arzneim.- Forsch. Drug Res. 49 1999 1035 1038
18. L. Zhai, M. Chen, J. Blom, T.G. Theander, S.B. Christensen, and A. Kharazmi Antimicrob. Agents Chemother. 43 1999 793 803
19. P.J. Declerq, and C.J. Deranter Biochem. Pharmacol. 35 1986 59 61
20. B. Enanga, M.R. Ariyanayagam, M.L. Stewart, and M.P. Barrett Antimicrob. Agents Chemother. 47 2003 3368 3370
21. J.D. Maya, S. Bollo, L.J. Nunez-Vergara, J.A. Squella, Y. Repetto, A. Morello, J. Ṕrí, and G. Chauvìre Biochem. Pharmacol. 65 2003 999 1006
22. R. Docampo, and S.N.J. Moreno Rev. Infect. Dis. 6 1984 223 238
23. C.M. Sreider, L. Grinblat, and A.O.M. Stoppani Biochem. Pharmacol. 40 1990 1849 1857
24. L.R. Berube, S. Farah, R.A. Mc Clelland, and A.M. Rauth Biochem. Pharmacol. 42 1991 2153 2161
25. E. Cadenas Annul. Rev. Biochem. 110 1989 58 79